Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type

Kwang Sik Kim, Alan S. Cross, Jerald Sadoff

Research output: Contribution to journalArticlepeer-review

Abstract

In an effort to develop more effective therapy for neonatal K1 Escherichia coli infection, a murine hybridoma antibody to the O-side chain of E. coli lipopolysaccharides (LPS) and cefotaxime, alone and in combination, were evaluated for their therapeutic efficacy against experimental K1 E. coli infection due to a homologous O serotype in newborn rats. Infected rats received either the LPS antibody (3 mg kg-1), cefotaxime (100 mg kg-1 day-1) or a combination of the two. Overall, the survival rate of animals receiving cefotaxime (46%) was significantly greater than that of animals receiving the LPS antibody alone (20%). It is of interest that the combination of cefotaxime and the LPS antibody was significantly more beneficial than either agent alone, as shown by a greater survival rate (73%). These findings suggest that immunotherapy with antibodies directed to O-LPS may be a useful adjunct to antimicrobial chemotherapy in neonatal E. coli infection.

Original languageEnglish (US)
Pages (from-to)95-99
Number of pages5
JournalSerodiagnosis and Immunotherapy in Infectious Disease
Volume4
Issue number2
DOIs
StatePublished - Apr 1990
Externally publishedYes

Keywords

  • Escherichia coli
  • anti-LPS antibody
  • immunotherapy
  • neonates

ASJC Scopus subject areas

  • Immunology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type'. Together they form a unique fingerprint.

Cite this